Yun Jang-Hyuk, Noh Yoo Rim, Yoo Seongkyeong, Park Soohyun, Choi Yunsup, An Jiyeon, Kim Iljin
College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 24341, Republic of Korea.
Department of Pharmacology and Program in Biomedical Science and Engineering, Inha University College of Medicine, Incheon 22212, Republic of Korea.
Pharmaceutics. 2025 Apr 17;17(4):528. doi: 10.3390/pharmaceutics17040528.
Ovarian cancer remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis, high recurrence rates, and the development of chemoresistance. Although targeted therapies have improved patient outcomes, their efficacy is often limited by off-target toxicity and acquired drug resistance. Extracellular vesicles (EVs), nanoscale vesicles naturally released by cells, have emerged as promising carriers for precision drug delivery. This review provides a comprehensive overview of recent advances in EV-based therapeutic strategies for ovarian cancer, including the delivery of chemotherapeutic agents, nucleic acid therapeutics, and immunomodulatory molecules. We further explore innovative engineering approaches to enhance targeting specificity, such as surface modification, cell source selection, biomaterial integration, and magnetic nanoparticle-assisted delivery. Key translational challenges in bringing EV-based therapies to clinical application are also addressed. Collectively, these insights underscore the transformative potential of EV-based platforms in advancing targeted and personalized treatment for ovarian cancer.
卵巢癌仍然是最致命的妇科恶性肿瘤之一，主要原因是晚期诊断、高复发率以及化疗耐药性的产生。尽管靶向治疗改善了患者的治疗效果，但其疗效常常受到脱靶毒性和获得性耐药性的限制。细胞外囊泡（EVs）是细胞自然释放的纳米级囊泡，已成为精准药物递送的有前景的载体。本文综述了基于EVs的卵巢癌治疗策略的最新进展，包括化疗药物、核酸治疗药物和免疫调节分子的递送。我们进一步探索了增强靶向特异性的创新工程方法，如表面修饰、细胞来源选择、生物材料整合和磁性纳米颗粒辅助递送。还讨论了将基于EVs的疗法应用于临床的关键转化挑战。总的来说，这些见解强调了基于EVs的平台在推进卵巢癌靶向和个性化治疗方面的变革潜力。
